Oslo, 7 May 2026 - Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-
the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the
treatment of solid cancers, today presents its results for the first quarter
2026.
Webcast scheduled for 7 May 2026 at 08:30 CET. Link to webcast here
(https://qcnl.tv/p/iBUW_URuMrVxcAaTkR-XDg).
Operational Highlights Q1 2026:
* First clinical site activated:
As announced yesterday, Zelluna has activated its first clinical site, The
Christie NHS Foundation Trust in the United Kingdom. This marks the
transition from clinical preparation to the execution phase of the ZIMA-101
study. Activation of the second clinical site, The Royal Marsden, is
expected in the near term.
* CTA approval:
On 20 February 2026, Zelluna announced that the Medicines and Healthcare
products Regulatory Agency (MHRA) and Research Ethics Committee (REC) had
approved the Company's Clinical Trial Application (CTA) for ZIMA-101, a
first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead
TCR-NK product candidate.
* Collaboration with Etcembly Ltd:
On 9 March 2026, the Company announced a collaboration with Etcembly Ltd to
leverage AI-enabled TCR engineering to develop KKLC1-targeting TCRs.
* Medpace selected as CRO:
On 11 February 2026, Zelluna announced that it had entered into a clinical
partnership with Medpace to support the Phase 1 trial of ZI-MA4-1 (ZIMA-
101).
Financial Highlights Q1 2026
* Total operating expenses: MNOK 20.4
* Total loss: MNOK 20.4
* Cash and cash equivalents: MNOK 49.3 as of 31 March 2026
* Financial runway: into Q1 2027
"Q1 2026 marked a major step forward for Zelluna as we moved from regulatory
submission into the clinic, following approval of our CTA for ZI-MA4-1 and
activation of our first clinical site, announced earlier today. As we progress
through 2026, our priorities are clear: dose the first patients in the ZIMA-101
study and execute with discipline as we begin generating clinical data in
patients. In parallel, we will continue to selectively advance our pipeline to
build on the long-term potential of the TCR-NK platform," says CEO Namir Hassan.
Outlook
Zelluna enters 2026 with its lead programme, ZI-MA4-1, progressing toward first
clinical evaluation in patients following successful GMP manufacturing and CTA
approval in the UK. As announced earlier today, the Phase 1 study ZIMA-101 is
now underway following activation of the first clinical site. Initial clinical
data are expected from mid-2026. The current cash position is expected to
support operations into Q1 2027.
The quarterly report and presentation will be made publicly available on the
Zelluna website. The Company will host a webcast on 7 May at 08:30 CET, and
questions can be submitted throughout the event. The webcast will be archived
for replay following the conference call. Link to webcast here
(https://qcnl.tv/p/iBUW_URuMrVxcAaTkR-XDg).
For further information, please visit www.zelluna.com
(http://www.zelluna.com/) or contact:
Namir Hassan, CEO
Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)
Phone: +44 7720 687608
Geir Christian Melen, CFO
Email: geir.christian.melen@zelluna.com
(mailto:geir.christian.melen@zelluna.com)
Phone: +47 913 02 965
About Zelluna ASA
Zelluna ASA (OSE: ZLNA) is a pioneering allogeneic 'off-the-shelf' T Cell
Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers.
The company's platform combines the innate killing power of NK cells with
precise solid tumour targeting of TCRs, designed to address the limitations of
current cell therapies in solid tumours. The company's lead candidate, ZI-MA4-
1, is the world's first MAGE-A4 targeting TCR-NK therapy in clinical
development. Zelluna is headquartered at the Oslo Cancer Cluster Innovation Park
in Oslo, Norway and is listed on the Oslo Stock Exchange under the ticker ZLNA.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act and the EU Market Abuse Regulation.